UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 24, 2021
SIGILON THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware | 001-39746 | 47-4005543 | |
(State or other jurisdiction | (Commission | (IRS Employer | |
of incorporation) | File Number) | Identification No.) | |
| | ||
100 Binney Street, Cambridge, MA | 02142 | ||
(Address of principal executive offices) | (Zip Code) | ||
(Registrant’s telephone number, including area code): (617) 336-7540
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| | Trading | | Name of each exchange |
Title of each class |
| Symbol(s) |
| on which registered |
Common Stock, $0.001 par value per | | SGTX | | The Nasdaq Global Select Market |
share | | | | |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders
On June 24, 2021, Sigilon Therapeutics, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”). The following is a brief description of each proposal voted upon at the Annual Meeting and the final voting results for each such proposal.
Proposal 1: Election of Directors
The director nominees listed below were elected to serve on the Company’s Board of Directors as members of Class I for a term of three years. The results of the vote were as follows:
Name of Nominee | For | Against | Abstain | Broker Non-Votes | ||||
Eric Shaff |
| 17,216,050 | 1,881,959 | 14,419 | 1,150,613 | |||
Robert Ruffolo, Jr., Ph.D. |
| 17,151,599 | 1,946,565 | 14,264 | 1,150,613 |
Proposal 2: Ratification of the Company’s Independent Registered Public Accounting Firm
The stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ended December 31, 2021. The results of the vote were as follows:
For | Against | Abstain | ||
20,196,864 |
| 5,233 |
| 60,944 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| SIGILON THERAPEUTICS, INC. | |
| | |
| By: | /s/ Matthew P. Kowalsky |
| | Matthew P. Kowalsky |
| | Chief Legal Officer and Corporate Secretary |
Date: June 28, 2021